Carisma Therapeutics Future Growth
Future criteria checks 2/6
Carisma Therapeutics is forecast to grow earnings and revenue by 17% and 33.1% per annum respectively while EPS is expected to grow by 27.6% per annum.
Key information
17.0%
Earnings growth rate
27.6%
EPS growth rate
| Biotechs earnings growth | 24.6% |
| Revenue growth rate | 33.1% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 23 Apr 2024 |
Recent future growth updates
Recent updates
Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 26%
Apr 19
We're A Little Worried About Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Rate
Mar 26Lacklustre Performance Is Driving Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 26% Price Drop
Jan 21The Market Doesn't Like What It Sees From Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Revenues Yet As Shares Tumble 27%
Dec 07Analyst Forecasts Just Became More Bearish On Carisma Therapeutics, Inc. (NASDAQ:CARM)
Nov 12Here's Why We're Watching Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Situation
Oct 05We're Hopeful That Carisma Therapeutics (NASDAQ:CARM) Will Use Its Cash Wisely
Jun 15Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 23 | -69 | -39 | -56 | 3 |
| 12/31/2025 | 14 | -70 | -54 | -55 | 5 |
| 12/31/2024 | 17 | -58 | -35 | -35 | 5 |
| 12/31/2023 | 15 | -87 | -82 | -81 | N/A |
| 9/30/2023 | 14 | -83 | -83 | -82 | N/A |
| 6/30/2023 | 13 | -80 | -73 | -70 | N/A |
| 3/31/2023 | 12 | -75 | -69 | -65 | N/A |
| 12/31/2022 | 10 | -61 | -10 | -5 | N/A |
| 9/30/2022 | 6 | -57 | -2 | 3 | N/A |
| 6/30/2022 | 4 | -49 | -1 | 2 | N/A |
| 3/31/2022 | 1 | -43 | 4 | 7 | N/A |
| 12/31/2021 | N/A | -41 | -39 | -37 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CARM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CARM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CARM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CARM's revenue (33.1% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: CARM's revenue (33.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CARM's Return on Equity is forecast to be high in 3 years time